259 related articles for article (PubMed ID: 26300318)
21. Regulation of adipokines by polyunsaturated fatty acids in a rat model of non-alcoholic steatohepatitis.
Ding WJ; Wang Y; Fan JG
Arch Iran Med; 2014 Aug; 17(8):563-8. PubMed ID: 25065280
[TBL] [Abstract][Full Text] [Related]
22. Effectiveness of Omega-3 Polyunsaturated Fatty Acids in Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials.
He XX; Wu XL; Chen RP; Chen C; Liu XG; Wu BJ; Huang ZM
PLoS One; 2016; 11(10):e0162368. PubMed ID: 27711128
[TBL] [Abstract][Full Text] [Related]
23. NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs.
Caldwell S
Clin Mol Hepatol; 2017 Jun; 23(2):103-108. PubMed ID: 28494529
[TBL] [Abstract][Full Text] [Related]
24. Dietary lipids and NAFLD: suggestions for improved nutrition.
Molendi-Coste O; Legry V; Leclercq IA
Acta Gastroenterol Belg; 2010; 73(4):431-6. PubMed ID: 21299150
[TBL] [Abstract][Full Text] [Related]
25. The role of the microbiome in NAFLD and NASH.
Kolodziejczyk AA; Zheng D; Shibolet O; Elinav E
EMBO Mol Med; 2019 Feb; 11(2):. PubMed ID: 30591521
[TBL] [Abstract][Full Text] [Related]
26. Modulation of Gut Microbiota by Berberine Improves Steatohepatitis in High-Fat Diet-Fed BALB/C Mice.
Cao Y; Pan Q; Cai W; Shen F; Chen GY; Xu LM; Fan JG
Arch Iran Med; 2016 Mar; 19(3):197-203. PubMed ID: 26923892
[TBL] [Abstract][Full Text] [Related]
27. Review article: emerging role of the gut microbiome in the progression of nonalcoholic fatty liver disease and potential therapeutic implications.
Jayakumar S; Loomba R
Aliment Pharmacol Ther; 2019 Jul; 50(2):144-158. PubMed ID: 31149745
[TBL] [Abstract][Full Text] [Related]
28. Exendin‑4, a glucagon‑like peptide‑1 receptor agonist, modulates hepatic fatty acid composition and Δ‑5‑desaturase index in a murine model of non‑alcoholic steatohepatitis.
Kawaguchi T; Itou M; Taniguchi E; Sata M
Int J Mol Med; 2014 Sep; 34(3):782-7. PubMed ID: 24993337
[TBL] [Abstract][Full Text] [Related]
29. Nutritional therapy for nonalcoholic fatty liver disease.
Dongiovanni P; Lanti C; Riso P; Valenti L
J Nutr Biochem; 2016 Mar; 29():1-11. PubMed ID: 26895659
[TBL] [Abstract][Full Text] [Related]
30. The Gut Microbiota and Nonalcoholic Fatty Liver Disease.
Quigley EM; Monsour HP
Semin Liver Dis; 2015 Aug; 35(3):262-9. PubMed ID: 26378643
[TBL] [Abstract][Full Text] [Related]
31. Influence of gut microbiota on the development and progression of nonalcoholic steatohepatitis.
de Faria Ghetti F; Oliveira DG; de Oliveira JM; de Castro Ferreira LEVV; Cesar DE; Moreira APB
Eur J Nutr; 2018 Apr; 57(3):861-876. PubMed ID: 28875318
[TBL] [Abstract][Full Text] [Related]
32. Gut-liver axis, nutrition, and non-alcoholic fatty liver disease.
Kirpich IA; Marsano LS; McClain CJ
Clin Biochem; 2015 Sep; 48(13-14):923-30. PubMed ID: 26151226
[TBL] [Abstract][Full Text] [Related]
33. Non-alcoholic fatty liver and the gut microbiota.
Bashiardes S; Shapiro H; Rozin S; Shibolet O; Elinav E
Mol Metab; 2016 Sep; 5(9):782-94. PubMed ID: 27617201
[TBL] [Abstract][Full Text] [Related]
34. Intestinal microbiota and nonalcoholic steatohepatitis.
Brandl K; Schnabl B
Curr Opin Gastroenterol; 2017 May; 33(3):128-133. PubMed ID: 28257306
[TBL] [Abstract][Full Text] [Related]
35. Design and rationale of the WELCOME trial: A randomised, placebo controlled study to test the efficacy of purified long chainomega-3 fatty acid treatment in non-alcoholic fatty liver disease [corrected].
Scorletti E; Bhatia L; McCormick KG; Clough GF; Nash K; Calder PC; Byrne CD;
Contemp Clin Trials; 2014 Mar; 37(2):301-11. PubMed ID: 24556343
[TBL] [Abstract][Full Text] [Related]
36. The Role of Probiotics in Nonalcoholic Fatty Liver Disease: A New Insight into Therapeutic Strategies.
Meroni M; Longo M; Dongiovanni P
Nutrients; 2019 Nov; 11(11):. PubMed ID: 31689910
[TBL] [Abstract][Full Text] [Related]
37. Mouse models of nonalcoholic steatohepatitis in preclinical drug development.
Hansen HH; Feigh M; Veidal SS; Rigbolt KT; Vrang N; Fosgerau K
Drug Discov Today; 2017 Nov; 22(11):1707-1718. PubMed ID: 28687459
[TBL] [Abstract][Full Text] [Related]
38. Anti-inflammatory activities of green tea catechins along the gut-liver axis in nonalcoholic fatty liver disease: lessons learned from preclinical and human studies.
Hodges JK; Sasaki GY; Bruno RS
J Nutr Biochem; 2020 Nov; 85():108478. PubMed ID: 32801031
[TBL] [Abstract][Full Text] [Related]
39. Impact of dietary fat on the development of non-alcoholic fatty liver disease in Ldlr-/- mice.
Jump DB; Depner CM; Tripathy S; Lytle KA
Proc Nutr Soc; 2016 Feb; 75(1):1-9. PubMed ID: 26282529
[TBL] [Abstract][Full Text] [Related]
40. Nonalcoholic Fatty Liver Disease (NAFLD) as Model of Gut-Liver Axis Interaction: From Pathophysiology to Potential Target of Treatment for Personalized Therapy.
Fianchi F; Liguori A; Gasbarrini A; Grieco A; Miele L
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34204274
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
